0001225208-24-003056.txt : 20240227 0001225208-24-003056.hdr.sgml : 20240227 20240227134743 ACCESSION NUMBER: 0001225208-24-003056 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240223 FILED AS OF DATE: 20240227 DATE AS OF CHANGE: 20240227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McDermott Michael CENTRAL INDEX KEY: 0001902464 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 24684959 MAIL ADDRESS: STREET 1: C/O PFIZER INC. CORPORATE SECRETARY STREET 2: 235 EAST 42ND STREET CITY: 235 EAST 42ND STREET STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 4 1 doc4.xml X0508 4 2024-02-23 0000078003 PFIZER INC PFE 0001902464 McDermott Michael 66 HUDSON BOULEVARD EAST ATTN: CORPORATE SECRETARY NEW YORK NY 10001-2192 1 Executive Vice President 0 Common Stock 2024-02-23 4 M 0 12412.0000 27.3400 A 95408.0000 D Common Stock 2024-02-23 4 F 0 859.0000 27.7600 D 94549.0000 D Common Stock 2024-02-23 4 F 0 10031.0000 27.3700 D 84518.0000 D Common Stock 2024-02-25 4 F 0 2992.0000 27.7600 D 81526.0000 D Common Stock 2024-02-26 4 F 0 6063.0000 27.1800 D 75463.0000 D Stock Appreciation Rights 27.3400 2024-02-23 4 M 0 12412.0000 0.0000 D 2024-02-23 2024-02-23 Common Stock 12412.0000 0.0000 D The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Price is the closing price of Pfizer common stock on February 23, 2024. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Susan E. Grant, by power of atty., for Michael McDermott 2024-02-27